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Deiodinases are selenoenzymes that catalyze thyroid hormones (THs) activation (type 1
and type 2, D1 and D2, respectively) or inactivation (type 3, D3).THs are essential for proper
body development and cellular differentiation. Their intra- and extra-cellular concentrations
are tightly regulated by deiodinases with a pre-receptorial control thus generating active or
inactive form of THs. Changes in deiodinases expression are anatomically and temporally
regulated and influence the downstream TH signaling. D3 overexpression is a feature of
proliferative tissues such as embryo or cancer tissues.The enhancedTH degradation by D3
induces a local hypothyroidism, thus inhibitingTHs transcriptional activity. Of note, overex-
pression of D3 is a feature of several highly proliferative cancers. In this paper, we review
recent advances in the role of D3 in cancer growth, stemness, and metabolic phenotype.
In particular, we focus on the main signaling pathways that result in the overexpression
of D3 in cancer cells and are known to be relevant to cancer development, progression,
and recurrence. We also discuss the potential role of D3 in cancer stem cells metabolic
phenotype, an emerging topic in cancer research.
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INTRODUCTION
Thyroid hormones (THs) are iodinated compounds known to
regulate a wide range of cellular activities through TH receptors
(TRs). These are sequence-specific ligand-dependent transcrip-
tion factors that trigger many of the THs downstream effects by
activating or repressing target genes. TH functions are impor-
tant for development, tissue differentiation, and maintenance of
cell metabolic balance (1). Severe disruption of TH action dur-
ing fetal and early neonatal development leads to permanent
deficits (2).
Deiodination is a critical process by which the less active
hormone thyroxin (T4) is converted into the more active form,
triiodothyronine (T3). Deiodinases exert a major metabolic con-
trol of intracellular TH concentrations leading to a tissue-specific
TH bioavailability. D2 and D3 are widely expressed but they are
dynamically and tightly coordinated allowing cells to adapt their
own TH activity. In contrast, the role of D1 is primarily to provide
T3 for the circulation and it is highly expressed in the liver, kidney,
and thyroid (3).
D3 is the physiological inactivator of TH that acts by deiodinat-
ing the inner ring of T3 and T4 hormones to give T2 and reverse T3,
respectively. So far, this enzyme controls local TH homeostasis and
protects tissues from TH excess. Local deiodination represents an
example of cell-autonomous, pre-receptoral control of TH action
showing that TH signaling can be different in tissues even in the
presence of the same serum hormone concentration (4, 5).
D3 plays a major role in lowering serum TH concentrations
during development. Furthermore, the expression levels and activ-
ity of D3 significantly increase in the embryo tissues such as liver,
cerebral cortex, gonads, umbilical arteries and vein, lung, heart,
intestine, and skin (6) compared to the adult tissues. D3 is also
highly expressed in the human placenta where it has to reduce
fetal tissues exposure to TH. In contrast, D3 activity has been
identified in a limited number of postnatal tissues as brain, skin,
and pregnant uterus.
Mouse model of D3 deficiency (D3KO) has been pivotal in
current understanding of the functional role of D3. D3KO mice
showed impaired fertility, significant perinatal mortality, and
growth impairment. In addition, the hypothalamic–pituitary–
thyroid (HPT) axis development was altered probably for the
overexposure to excessive levels of THs (7). Notably, these abnor-
malities resemble those observed in children exposed to high
levels of THs because of their mothers’ hyperthyroidism during
pregnancy (8, 9).
Overall, these findings point out the key role of D3 in cell
proliferation and differentiation in normal and pathological con-
ditions. In particular, several studies, recently reviewed by Casula
and Bianco (10),demonstrated that the local control of THs signal-
ing provided by the regulation of D3 activity is strictly associated
to cancer development, progression, and recurrence.
This review focuses on the most recent progresses achieved in
this field, particularly the physiological function and significance
of D3 in the stemness and metabolic features of cancer cells.
TYPE 3 DEIODINASE: ROLE AND FUNCTIONS IN NORMAL
AND CANCER TISSUES
D3 has been defined as an “oncofetal” protein because highly
expressed during embryonic development and cancer. Beyond
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its considerable role in protecting tissues from excessive TH lev-
els during embryogenesis, D3 exerts a relevant function also in
adult life. Several studies revealed that signals such as hypoxia
or ischemia induce D3 re-expression in pathological conditions
as cancer, cardiac hypertrophy, myocardial infarction, chronic
inflammation, and critical illness, indicating that cell-specific TH
inactivation is critical in these conditions (11, 12). In adult life,
D3 expression ceases and switches on upon tumoral transforma-
tion, while it remains silent in the normal counterpart tissues. D3
reactivation in adult tissues has been correlated with hyperprolif-
erative conditions and has been found in human solid tumors. This
finding suggests a link between deiodinase-mediated TH metab-
olism and carcinogenesis. Indeed, D3-mediated local hypothy-
roidism promotes cellular proliferation by regulating the nuclear
T3 availability.
It has been reported that immortalized cell lines derived from
different tumors such as basal-cell carcinoma (BCC), heman-
giomas, hepatocarcinomas, breast cancer (MCF-7 cells), colon
adenocarcinoma (Caco2, SW280, and HCT116 cells), thyroid
cancer, endometrium cancer (ECC-1 cells), and neuroblastoma
(SH-SY5Y cells) express elevated D3 levels (13–16).
D3 overexpression has been further verified in many human
cancer tissues. Vascular tumors (hepatic hemangiomas) show high
D3 activity resulting in an accelerated rate of THs degradation
leading to a clinically relevant hypothyroidism named “consump-
tive hypothyroidism” (17, 18). Elevated levels of D3 decrease
nuclear TH availability in BCC cells compared to normal ker-
atinocytes, probably enhancing the proliferation rate of these cells.
D3 is also up-regulated in papillary thyroid cancer (PTC) with
tumors harboring BRAFV600E mutation having the highest levels
of D3 activity. In those cancers, increased D3 activity positively
correlates with tumor size and disease spread (19). Since thyroid
cancer is characterized by altered tumor suppressor p53 family
members expression (20–23), it should be interesting to analyze if
there is any correlation with deiodinases deregulation. We could
also hypothesize that restoration of tumor suppressor activity (24)
could modify D3 expression.
In benign adenomas and in colon carcinomas, D3 expression
is significantly higher than in normal tissues but negatively cor-
related with the histologic grade of the lesions suggesting that D3
could be a marker of the early stages of tumorigenesis (16).
MOLECULAR MECHANISMS OF D3 REGULATION IN
CELLULAR PATHWAYS INVOLVED IN STEMNESS
Several signaling molecules involved in the control of cell prolifera-
tion such as hormones and growth factors stimulate D3 expression.
Estrogens and progesterone independently increase D3 expression
in the uterus (6). Furthermore, D3 expression is strongly induced
by epidermal (EGF) and fibroblast growth factors (FGF) (25). In
in vitro experiments on astrocytes and preadipocytes, serum and
phorbol esters induce D3 expression (26), a stimulatory effect that
appears to be mediated, at least in part, by the activation of the
MEK/ERK signaling cascade (27). Notably, D3 expression is under
the control of signaling pathways linked to stemness and involving
sonic hedgehog-glioma associated oncogene 2 (Shh-Gli2), Wnt/β-
catenin, tumor growth factor-β (TGF-β), and hypoxia-inducible
factor-1α (HIF-1α) (16, 28–31) (Table 1).
Table 1 | Hormones and intracellular pathways inducing D3
overexpression and subsequently local hypothyroidism.
D3 inducers Involvement in cancer
cell stemness
Estrogen Bates et al. (6)
Progesteron Bates et al. (6)
EGF Hernandez et al. (25)
FGF Hernandez et al. (25)
Serum Courtin et al. (26)
Phorbol compounds Courtin et al. (26)
Shh-Gli2 Dentice et al. (28) Ahn et al. (37); Bhardwaj
et al. (35); Goodrich et al.
(41); Paladini et al. (77)
Wnt/β-catenin Dentice et al. (16) Sirakov et al. (48)
TGF-β Huang et al. (29) Massague et al. (50)
HIF-1α Simonides et al. (31) Keith et al. (57); Li et al. (58);
Wang et al. (59); Ciavardelli
et al. (62); Morfouace et al.
(65)
Pathways significantly involved in cancer stemness are also shown.
THE HEDGEHOG CASCADE
Vertebrates possess three hedgehog (Hh) proteins, Sonic hedgehog
(Shh), Indian hedgehog (Ihh), and Desert hedgehog (Dhh), all of
which bind to the receptor patched homolog-1 (PTCH-1). SHH
is the best-studied ligand of the vertebrate pathway that signals in
an autocrine or paracrine fashion (32).
In the absence of the SHH ligand, PTCH-1 inhibits a down-
stream protein in this pathway named Smoothened (SMO).
PTCH-1 removes oxysterols from SMO reducing its activity (33).
Upon binding of an Hh protein or a mutation of PTCH, SMO
oxysterols increase. This accumulation allows SMO to activate the
zinc-finger transcription factors Gli. The sequence of the molecu-
lar events that connect SMO to Gli is not completely understood.
Activated Gli accumulates in the nucleus and controls the tran-
scription of hedgehog target genes that play important roles in a
wide variety of developmental processes (34). Indeed, disruption
of hedgehog signaling during embryonic development, through
either deleterious mutation or consumption of teratogens by the
gestating mother, can cause severe developmental abnormalities.
However, Hedgehog signaling has an important role even in the
adult life. SHH has been shown to promote adult stem cells pro-
liferation in many tissues including primitive hematopoietic cells
(35), mammary (36), and neural stem cells (37).
Of note, abnormal activation of this pathway probably leads to
transformation of adult stem cells into cancer stem cells (CSCs). In
fact, it has been implicated in the development of cancers in brain,
lung, mammary gland, prostate, and skin (38, 39). BCC, the most
common cancer of hair follicle-derived tumors in humans, has the
closest association with the hedgehog signaling (40). Furthermore,
loss-of-function mutations in PTCH (41) and activating muta-
tions in SMO have been identified in patients with this disease (40).
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There are several evidences that D3 is under the control of
the Shh–Gli pathway. The activation of this pathway results in
D3 overexpression in mouse and human BCC (28). By directly
inducing D3 in keratinocytes, Shh causes a hypothyroid state at
intracellular level resulting in a higher proliferative rate. Further-
more, during development another member of the Hh family, Ihh,
reduces intracellular T3 availability by inducing D2 ubiquitination
and degradation (42). However, the mechanisms that link the reg-
ulation of T3, via deiodinase action, to the Hh pathway are still
unclear. In most adult tissues, Gli proteins have a short half-life
and are poorly detectable, because of their rapidly degradation by
proteasomes. Conversely, Hh-induced BCC tumorigenesis causes
Gli protein stabilization and accumulation (43). It has been shown
that D3 expression in BCC cells determines a proliferative advan-
tage for the tumor and that, conversely, D3 depletion interferes
with tumorigenesis, enhancing the apoptotic process. By pro-
moting Gli degradation, T3 blocks its transcriptional activity.
Moreover, T3 treatment or D3 depletion reduce tumor growth in
a genetically modified mouse model of skin tumorigenesis. By this
mechanism, Shh induces TH signaling attenuation contributing
to epidermal tumorigenesis in vivo by favoring cell proliferation
and bypassing T3-induced growth arrest and cell differentiation.
THE WNT/β-CATENIN SIGNALING
Wnt signaling is activated when specific ligands bind to friz-
zled and low-density lipoprotein receptor-related protein (LRP)
receptors, allowing stabilization and nuclear translocation of
β-catenin (44). The interaction between E-cadherin and the
cytoskeleton with β-catenin participates in the regulation of actin
filament assembly and cell adhesion (45). A complex of several
protein kinases that promote β-catenin degradation regulates its
cellular localization. In the presence of Wnt ligands, this complex
is blocked so that β-catenin accumulates and translocates to the
nucleus modulating Wnt target genes expression (44).
The Wnt genes encode a large family of cysteine-rich secreted
polypeptides that mediate different signaling processes. Deregula-
tion of Wnt signaling causes developmental defects and tumorige-
nesis (46). Indeed, the Wnt/β-catenin signaling pathway is dereg-
ulated in many colon tumors (16). As Wnt/β-catenin, also THs are
involved in the control of intestinal development and proliferation,
in fact in amphibian metamorphosis, they control gastrointestinal
tract remodeling (47).
It has been recently shown that Wnt/ β-catenin pathway directly
affects TH signaling by a dual convergent mechanism, which mod-
ulates the activity of the deiodinase enzymes in colon cancer cells
(16). Specifically, the TH activating D2 enzyme is down-regulated
by β-catenin while D3 is over-expressed. Similarly to colon can-
cer, it should be postulated that deregulated Wnt pathway could
induce D3 expression in other tumors.
In the intestinal epithelium, several signaling pathways includ-
ing Wnt and TH are fundamental during development. In the
adult life, they participate to maintain epithelial homeostasis and
renewal through the intestinal stem cells localized in the crypt
base. It has been demonstrated that, in the intestinal epithe-
lium, precursor cells interact with the Wnt pathway molecules
through their TRs. This interaction controls crypt proliferation
in physio-pathological conditions (48). Interestingly, the same
pathways are involved in retina development and may control
the balance of adult stem/progenitor cells. Therefore, the cross-
regulation between TRs and the Wnt pathway could be important
in the adult stem cells biology, as demonstrated in both retina and
intestinal systems.
THE TGF-β SIGNALING
TGF-β family members control cell differentiation, migration,
growth, and neoplastic transformation (49, 50). The classic TGF-
β signaling cascade is a linear pathway involving two cell surface
receptor kinases that, when activated, phosphorylate one or more
Smad proteins, causing them to enter the nucleus and activate
target gene transcription (50–52). Regulation by TGF-β can syn-
ergize with other ligands such as TPA, EGF, and FGF, known to
signal through trans-membrane receptor tyrosine kinases.
Of note, TGF-β regulates THs signaling. In fact, D3 mRNA
is transcriptionally stimulated by TGF-β in different human cell
types including fetal and adult fibroblasts, fetal epithelia, skele-
tal muscle myoblasts, uterine endometrium, hemangioma cells,
and gliomas (29). As described for other pathways, local hypothy-
roidism induced by TGF-β could facilitate the expression of
oncofetal genes and inhibit the differentiation effects of TH or
promote cell survival in pathological conditions as ischemia or
inflammation reducing their metabolic requirements.
THE HIF-1 SIGNALING
Several tissues that express D3 are known to be hypoxic, including
normal tissues of the human fetus (53) and ischemic tissues
of critically ill patients (54). Local TH inactivation by D3 may
be an important component of the tissue response to different
hypoxic–ischemic injuries.
Although the regulation of D3 expression by oxygen availabil-
ity is cell-type specific, hypoxia increases D3 mRNA and activity
in different cell types. HIF-1α is the transcriptional mediator of
the cellular response to low oxygen and hypoxia mimetics such
as desferrioxamine (DFO) and CoCl2, which promote HIF-1α
stabilization and accumulation, also induce D3. In fact, strong
evidences show that D3 is a direct HIF-1 target gene. Increased D3
activity inhibits T3-stimulated metabolic rate in cells in vitro and
reduces specific T3 activities in vivo (31).
Because THs are potent stimulators of metabolic rate and oxy-
gen consumption, the regulation of local T3 action in hypoxic
tissues has important physiological consequences. Many HIF-1
target genes are known to promote the survival of hypoxic cells
(31). Noteworthy, endogenous D3 activity is a potent inhibitor of
T3-dependent oxygen consumption. This suggests a mechanism
of metabolic regulation during certain hypoxic–ischemic injuries
in which HIF-1-induced D3 promotes the viability of hypoxic
tissues by reducing T3-stimulated energy expenditure (31). The
T3-dependent reduction of oxygen consumption supports the
idea that D3 reactivation in certain conditions may be consid-
ered advantageous for the cell. Furthermore, the ability of D3 to
decrease the metabolic rate and the oxygen consumption is consis-
tent with the function of many other HIF-1 target genes (53). Of
note, hypoxia is a common feature of advanced solid tumors and
has been associated with poor therapeutic response and increased
risk of recurrence (55, 56). HIF has been shown to activate specific
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signaling pathways that control stem cell self renewal and multipo-
tency (57–59). However, several HIF-1 target genes, such as the key
enzymes of the first phase of cell respiration, are over-expressed in
cancer cells also upon normoxic conditions, resulting in increased
fermentative glycolysis. This phenomenon has been termed “the
Warburg effect” and has been associated to tumor progression and
aggressiveness (60). This may indicate that overexpression of D3
in cancer cells is not merely a response to hypoxia but may signif-
icantly contribute to the complex mechanisms that proliferating
cancer cells set in motion also upon normoxic condition in order
to decrease the energy substrate degradation, thus supporting the
diversion of metabolites into cellular biosynthetic pathways.
TYPE 3 DEIODINASE ANDWARBURG EFFECT
The study of cancer metabolism has recently gained great atten-
tion as pharmacological targeting of specific metabolic path-
ways is a promising therapeutic approach and cancer cell pro-
liferation is strictly related to significant alterations of cellular
metabolism (61).
As discussed above, cancer cells are characterized by increased
aerobic glycolysis and lactic acid production upon normoxic con-
dition compared to normal cells. Recent studies indicate that this
metabolic phenotype is strictly associated to the stemness of can-
cer cells (62–64). It is worthy of note that this metabotype is
linked to the increased chemoresistance of CSCs compared to
more differentiated tumor cells. In fact, pharmacological interven-
tions aimed to differentiate CSCs result in a metabolic shift from
aerobic glycolysis toward mitochondrial oxidative phosphoryla-
tion and increase cell death (65). As CSCs are involved in tumor
resistance, metastasis formation and reliance, the effective elimi-
nation of CSCs is critical for successful therapeutic outcomes (66,
67). Although it is well known that D3 promotes the proliferation
of malignant cells and tumor growth, it is still unclear whether
D3-induced local hypothyroidism may have a role in determining
the metabolic phenotype and aggressiveness of CSCs. In fact, data
on D3 activity and expression in CSCs are currently unavailable.
On the other hand, it is known that thyroid hormones (THs) T3
and T4 modulates Warburg phenotype in breast-cancer cells and
treatment with T3 decreases the tumor chemoresistance in vitro
inhibiting aerobic glycolysis and increasing mitochondrial activ-
ity and oxygen consumption (68). This finding suggests that the
increase of T4 and T3 deiodination by D3 could be associated to
more aggressive phenotypes.
As discussed above, D3 is involved in the adaptative response
to hypoxia in cells and is trascriptionally induced by HIF-1α (31)
as well as other molecular mediators of the Warburg effect such
as hexokinase, pyruvate kinase (PK), and lactate deydrogenase
(Figure 1). Notably, the embryonic and low activity isoform of
FIGURE 1 | Effects of type 3 deiodinase expression onWarburg
phenotype. Hypoxia or oncogenic signals inhibit HIF-1a degradation and
stabilize the nuclear association between HIF-1a and HIF-1b resulting in
the transactivation of HIF-1 target genes. The activation of the M2 isoform
of pyruvate kinase (PKM2), lactate dehydrogenase A (LDHA), and of the
pyruvate dehydrogenase kinase 1 (PDHK1) that, in turn, inhibits the
mitochondrial pyruvate dehydrogenase (PDH) shunts cell metabolism from
the mitochondrial respiration toward the fermentative glycolysis.
Furthermore, the induction of max interactor 1 (MXI1), a transcriptional
target of HIF-1 complex, inhibits mitochondrial biogenesis through the
downexpression of nuclearly encoded mitochondrial genes. The
coexpression of type 3 deiodinase (D3) decreases cytosolic
triiodothyronine (T3) levels resulting in the activation of PKM2. It is also
possible that D3 translocates from cytoplasm to the cell nucleus
mediating nuclear thyroid hormone inactivation and local hypothyroidism.
Bold arrows indicate activation, whereas the blunted lines indicate
inhibition. Dashed arrows indicate protein translocation between cellular
compartments. Dotted lines indicate the pathway reactions.
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PK, PKM2, is enriched in CSCs and promotes the aerobic glycolysis
thus contributing to anabolic metabolism. T3 has been reported
as an allosteric inhibitor of PKM2 in vitro (69, 70). Therefore,
the overexpression of D3 and the resulting decrease of cytoso-
lic T3 increase PKM2 activity stimulating the aerobic glycolysis
(Figure 1). Furthermore, in neurons, hypoxia induces heat-shock
protein-40 (Hsp-40)-mediated nuclear import of D3 that facilitate
THs inactivation resulting in nuclear hypothyroidism and reduc-
ing cellular metabolism and oxygen consumption (71). Although
this mechanism has not been yet reported in cancer cells, it is wor-
thy of note that Hsp-40, also known as DNAJB1, and the other
members of DNAJ family have been found to be involved in the
regulation of cancer cells and CSCs (72). The function of Hsp-40
is still controversial because this chaperone protein may inter-
act with PKM2 inducing its degradation and impairing tumor
cell proliferation (73). However, some CSCs isolated from specific
solid tumors display increased levels of Hsp-40 (74). Therefore, it
is intriguing to speculate that D3 could contribute to the glycolytic
phenotype of CSCs and therefore provide an additional target to
counteract CSCs metabolism.
CONCLUSION
At cellular level, TH signaling can be regulated by deiodinases
in a time- and tissue-specific fashion independently on plasma
thyroid hormone levels (11). Although it is not clear why deiodi-
nases expression is altered in cancer tissues, this could be used as
a marker of the disease. Nevertheless, changing in TH signaling
through deiodinase activation could play a role in cell prolifer-
ation or viability. Since attenuation of TH signaling is part of a
widespread neoplastic program, D3 expression may therefore be
one of the mechanisms used by cancer cells to get rid of the THs
differentiation action.
An increase in TH signaling accelerates the mitochondrial oxi-
dation of energy substrates such as glucose and fatty acids in most
cells types (75). As cancer cells and CSCs are known to mainly rely
on aerobic glycolysis (76) that is stimulated by cell hypothyroidism,
it is conceivable that deiodinases modulation could be a potential
therapeutic target for cancers that depend on high metabolic rate
and do not show deiodinases deregulation.
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